Sign in
4

Changes in Ownership

Nurix Therapeutics, Inc. Filed Acc 0001209191-23-026515

Chief Scientific Officer sold 1,136 shares at $9.88 ($11,219)

  • Chief Scientific Officer acquired 3,206 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Hansen Gwenn · Chief Scientific Officer

Table I: Non-derivative

2 lines
Date Transaction Shares Price Value Owned after D/I
2023-04-30 Exercise or conversion : show line 1 in the form +3,206 27,768 D
2023-05-01 Sale : show line 2 in the form −1,136 $9.88 $11,219 26,632 D
Open-market sales · 1,136 sh · avg $9.88 · $11,219

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2023-04-30 Exercise or conversion : show line 3 in the form Restricted Stock Units −3,206 35,275 D
Loading xslF345X04/doc4.xml…